SPERO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On September 6, 2022, Spero Therapeutics, Inc. issued a press release announcing an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration, discussing steps required for resubmission of the New Drug Application for tebipenem HBr for the treatment of complicated urinary tract infection, including pyelonephritis. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



99.1      Press Release, dated September 6, 2022

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses